Extracellular matrix (ECM) and basement membranes (BMs) present a physical barrier that requires enzymatic degradation during endothelial cell (EC) sprouting at early stages of angiogenesis. These multimolecular structures also serve as a storage depot for heparin-binding angiogenic factors. Heparan sulfate proteoglycans (HSPGs) are responsible for the self-assembly and integrity of the ECM and BM structure, as well as for sequestration of growth and differentiation factors. Recently, we reported the cloning of heparanase, an endo-β-Dglucuronidase degrading heparan sulfate (HS), and provided direct evidence for its role in tumor metastasis. We now demonstrate that heparanase is intimately involved in angiogenesis and elucidate its mode of action. Apart from its direct involvement in ECM degradation and EC migration (vascular sprouting), heparanase releases active basic fibroblast growth factor (bFGF) from the subendothelial ECM, as well as bFGF-stimulating HS degradation fragments from the EC surface. Interestingly, ECM-derived HS fragments induced little or no potentiation of the growth-promoting activity of bFGF. The angiogenic effect of heparanase was demonstrated in vivo (via the Matrigel plug assay) by showing a three-to fourfold increase in neovascularization induced by murine T-lymphoma cells after stable transfection with the heparanase gene. Increased tissue vascularity was also observed in a mouse wound-healing model in response to topical administration of recombinant heparanase. Immunohistochemical staining of human colon carcinoma tissue revealed a high expression of the heparanase protein in the endothelium of sprouting capillaries and small vessels, but not of mature quiescent blood vessels. The ability of heparanase to promote tumor angiogenesis and its involvement in tumor metastasis make it a promising target for cancer therapy.
the ECM and BM, such as collagen IV, laminin, and fibronectin. HSPGs are also actively involved in orchestrating cellular responses in both normal and pathological conditions (1, 2) , ranging from pregnancy and development to neovascularization and metastatic spread of malignant tumors.
The importance of HS and especially its enzymatic degradation during angiogenesis and metastasis has attracted growing attention during the last decade. Angiogenesis represents a coordinated multicellular process that requires the functional activity of a wide variety of molecules, including growth factors, ECM components, adhesion receptors, and matrixdegrading enzymes (3) . HS and HS-degrading enzymes are implicated in a number of angiogenesis-related cellular events, such as cell invasion, migration, adhesion, differentiation, and proliferation (1, 2) . An important early event in the angiogenic cascade is degradation of the subendothelial BM by proliferating ECs and formation of vascular sprouts (3, 4) . Enzymatic cleavage of HS, the polysaccharide scaffold of BM, is believed to contribute significantly to the invasive ability of ECs and their subsequent migration through the ECM toward the angiogenic stimulus.
Several species of HSPGs are not secreted into the ECM but are rather found on the cell surface (1) . Transmembrane and membrane-anchored HSPGs have a coreceptor role in which the HS, in concert with tyrosine kinase-signaling receptors, forms a functional complex that binds various members of the heparin-binding growth factor family, of which basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are regarded as the two major proangiogenic molecules (1) (2) (3) (5) (6) (7) (8) . Interactions of HS with bFGF have been studied extensively. bFGF requires HS as a cofactor for signaling. Cell surface HS bearing specific saccharide sequences functions as an accessory coreceptor for bFGF, facilitating high-affinity receptor binding and inducing bFGF receptor dimerization, autophosphorylation, and signaling (5) (6) (7) (8) (9) . ECM-and BM-resident HSPGs specifically bind bFGF and serve as its extracellular reservoir (6, 10) . Sequestration of bFGF by HSPGs in BM and ECM is well documented. bFGF was extracted from the subendothelial ECM in vitro and from both endothelial and epithelial BMs of the cornea and is distributed ubiquitously in BM of blood vessels of all sizes (6, 10) . Despite the ubiquitous presence of bFGF in normal tissues, EC proliferation in these tissues is usually very low, suggesting that bFGF is sequestered from its site of action (6, 10) . It appears that HS moieties are specific for binding and sequestration of bFGF in BM, as other glycosaminoglycans do not bind bFGF. In support of specific binding of bFGF to HS is the observation that up to 90% of the bound growth factor was displaced by heparin or HS (6, 10, 11) . It is conceivable that an enzyme (i.e., heparanase) degrading HS could mediate effective release of ECM-resident bFGF. Therefore, apart from direct involvement in BM invasion by ECs, degradation of HS may elicit an indirect angiogenic response by releasing HS-bound angiogenic growth factors (i.e., bFGF, VEGF) from ECM and BM (6, 10) and by generating HS fragments that can potentiate bFGF receptor binding, dimerization, and signaling (5) (6) (7) (8) .
On the basis of these considerations, we investigated the potential involvement of heparanase in neovascularization, both in vitro and in vivo. Endoglycosidic heparanase, degrading HS side chains of HSPGs, has been studied for its role in tumor progression during the last two decades (12) (13) (14) , but only recently have we and others cloned the mammalian heparanase gene (15) (16) (17) (18) (19) (20) and provided the first direct evidence for its role in tumor invasion and metastasis (15) . In the present study, the availability of recombinant heparanase, specific antibodies, and molecular probes enabled us to demonstrate a causative involvement of mammalian heparanase in angiogenesis associated with tumor progression and tissue repair, and to clarify its mode of action.
MATERIALS AND METHODS

Cells
The methylcholanthrene-induced nonmetastatic Eb T-lymphoma cells were grown in RPMI 1640 supplemented with 10% FCS (15) . Bovine aortic ECs, human umbilical vein ECs (HUVECs), and human bone marrow ECs (TrHBMECs) were cultured in Dulbecco's modified Eagle medium (DMEM) (1 g of glucose/liter) supplemented with 10% calf serum (Life Technologies, Grand Island, NY) and bFGF, as described previously (8, (21) (22) (23) . Bovine corneal ECs were established and maintained as described before (21) . Cells were cultured at 37°C in 10% CO 2 humidified incubators (21) . Clone F32 of BaF 3 lymphoid cells, kindly provided by Dr. D. Ornitz (Department of Molecular Biology, Washington University, St. Louis, MO), were grown in RPMI 1640 medium supplemented with 10% FCS, 10% interleukin 3-conditioned medium produced by X63-IL3 WHEI cells, L-glutamine, and antibiotics (8, 24) .
Recombinant heparanase
Recombinant heparanase was produced in stable transfected Chinese hamster ovary (CHO) cells. The entire open reading frame of heparanase was subcloned into the EcoRI-NotI sites of the mammalian expression vector pSI (Promega, Madison, WI), which was modified to harbor a dihydrofolate reductase expression cassette. The pSIhpa expression vector was transfected into CHO cells (15) , and recombinant heparanase was purified from cell extracts by using CMSepharose, heparin-Sepharose, and ConA-Sepharose columns, as previously described (25) .
Preparation of dishes coated with ECM
Bovine corneal ECs were cultured as described above except that 5% dextran T-40 was included in the growth medium and the cells were maintained without the addition of bFGF for 12 days (21). The subendothelial ECM was exposed by dissolving the cell layer with PBS containing 0.5% Triton X-100 and 20 mM NH 4 OH, followed by four washes in PBS (21) . The ECM remained intact, free of cellular debris, and firmly attached to the entire area of the tissue culture dish (21) . For preparation of sulfate-labeled ECM, corneal ECs were cultured in the presence of Na 2 [
35 S]O 4 (Amersham Pharmacia Biotech, Buckinghamshire, UK), added (25 •Ci/ml) on days 1 and 5 after seeding (21) . Ten to 12 days after seeding, the cell monolayer was dissolved and the ECM exposed, as described above.
Heparanase activity
Degradation of sulfate-labeled ECM by heparanase was determined as described before (12, 15, 21, 25) . Briefly, ECM was incubated (24 h, 37°C, pH 6.2) with recombinant heparanase or hpatransfected cells, and sulfate-labeled material released into the incubation medium was analyzed by gel filtration on a Sepharose 6B column (12, 15, 21, 25) . Intact HSPGs are eluted just after the void volume (K av < 0.2, fractions 1-10), and HS degradation fragments are eluted with 0.5 < K av < 0.8 (fractions 15-35) (12, 15, 21, 25) .
Release of ECM-bound bFGF
Recombinant bFGF was iodinated by using chloramine T and bound to ECM as described previously (11) . Briefly, tissue culture plates coated with ECM were incubated (3 h, 24°C) with 0.1 ng/ml 125 I-labeled bFGF in PBS containing 0.02% gelatin. Unbound bFGF was removed by three washes with PBS containing 0.02% gelatin. The ECM was then incubated with increasing concentrations (0.01-0.4 µg/ml) of recombinant heparanase at 37°C for 3 h. The incubation media were collected and counted in a γ counter to determine the amount of released 125 I-labeled bFGF. The remaining ECM was incubated (3 h, 37°C) with 1 N NaOH, and the solubilized radioactivity was counted in a γ counter. The percentage of released 125 I-labeled bFGF was calculated from the total ECM-associated radioactivity (11) .
Release of endogenous bFGF from ECM
ECM-coated 35-mm dishes were incubated (24°C, 4 h) with either 1 ml of heparanase reaction mixture (150 mM NaCl, 50 mM phosphate citrate buffer, pH 6.2, 0.2% bovine serum albumin), or reaction buffer containing 0.5 µg/ml recombinant heparanase. ELISA (Quantikine HS human FGF basic, R&D Systems, Minneapolis, MN) tested aliquots of the incubation medium for bFGF content. Each sample was tested in triplicate, and the variation between different determinations did not exceed ±7% of the mean.
Effect of HS fragments released by heparanase from cell surfaces and ECM on BaF 3 cell proliferation
Bovine aortic ECs and intact subendothelial ECM were incubated (4 h, 37°C) with 0.2 µg/ml heparanase. Increasing amounts of the incubation medium, containing approximately similar amounts of released HS degradation fragments, were then added to BaF 3 cells (2 × 10 4 cells/well; 96-well plate) in the presence of 5 ng/ml bFGF. Forty-eight hours later, [ 3 H]thymidine (1 µCi/well) (Amersham Pharmacia Biotech) was added for 6 h, followed by cell harvesting and measurement of [ 3 H]thymidine incorporation (8, 24) .
RNA isolation and reverse transcriptase-polymerase chain reaction (RT-PCR) assay
RNA from human ECs was isolated and 500 ng of total RNA was subjected to reverse transcription. The resulting single-stranded cDNA was amplified by PCR and human-specific oligonucleotide primers as described (15) . Aliquots (10 •l) of the amplification products were separated on a 1.5% agarose gel and visualized by ethidium bromide staining (15) .
Wound healing
Full-thickness wounds were created with an 8-mm punch on the dorsal skin of anesthetized BALB/c male mice. Purified 50-kDa active heparanase in phosphate citrate-buffered saline, pH 6.2, was applied topically twice a day at 0.1 µg/wound (~2 ng/mm 2 ) for 4 days, and once a day for the next 3 days. Control wounds were treated with buffered saline alone. For histological examination, wound areas, including the underlying granulation tissue, were excised and fixed with formalin. Paraffin-embedded sections were stained with hematoxylin and eosin.
Immunohistochemistry
Immunohistochemistry was performed as described before with minor modifications (15, 26) . Briefly, 5-µm sections were deparaffinized and rehydrated. Tissue was then denatured for 3 min in a microwave oven in citrate buffer (0.01 M, pH 6.0). Blocking steps included successive incubations in 0.2% glycine, 3% H 2 O 2 in methanol, and 5% goat serum. Sections were incubated with a monoclonal anti-human heparanase antibody (mAb 92.4) diluted 1:3 in PBS, or with DMEM supplemented with 3.3% horse serum as control, followed by incubation with horseradish peroxidase-conjugated goat anti-mouse IgG + IgM antibody (Jackson Laboratories, Bar Harbor, ME). mAb 92.4 is directed against the N-terminal region of the 50-kDa enzyme. The preparation and specificity of this mAb were previously described and demonstrated (15, 26) . Color was developed by using the Zymed AEC substrate kit (Zymed Laboratories, South San Francisco, CA) for 10 min, followed by counterstaining with Mayer's hematoxylin (15, 26) .
Immunostaining of blood vessels with anti-PECAM-1 antibodies was performed as previously described (27) . Briefly, sections were subjected to antigen retrieval, blocked with 10% normal horse serum, and incubated with polyclonal anti-PECAM-1 antibodies (1:100, Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C. Sections were then washed three times with PBS and visualized with Vectastain ABC kit and DAB substrate (Vector Laboratories, Burlingame, CA).
Matrigel plug assay
The Matrigel plug assay was performed as previously described (28) . Six-week-old male BALB/c mice (n = 5) were injected s.c. at the lateral abdominal area with 0.4 ml of Matrigel (kindly provided by Dr. H. Kleinmann, NIDR, NIH, Bethesda, MD) premixed on ice with 2 × 10 6 hpa-transfected Eb murine lymphoma cells (15) . Control mice were injected with Matrigel mixed with mock-transfected Eb cells, lacking heparanase. Matrigel plugs were removed 7 days postimplantation, photographed, and transferred to tubes containing 0.4 ml of dextrose in distilled water. Plugs were homogenized with a Politron homogenizer until complete disintegration. The debris was centrifuged and the hemoglobin-containing supernatant was collected. Hemoglobin content was determined by using the Drabkin reagent (Sigma, St. Louis, MO) and was quantitated against a standard curve of plasma hemoglobin.
RESULTS
Heparanase was expressed in the endothelium of angiogenic blood vessels but not of mature quiescent vessels of human tumors
We first investigated the expression of heparanase by vascular ECs in vitro and in angiogenic blood vessels. It was previously suggested that stimulated ECs secrete heparanase-like activity (22, 29). Using RT-PCR, we now demonstrate expression of the heparanase gene by proliferating human ECs. Both cultured HUVECs and TrHBMECs (23) expressed the heparanase gene, as reflected by a 564-bp PCR product (Fig. 1a) . Next, we subjected paraffinembedded sections of human colon adenocarcinoma tissue to immunohistochemical staining with monoclonal anti-heparanase antibodies. An interesting pattern of staining was noted in ECs from blood vessels of different maturation stages. It appears that the heparanase protein was preferentially expressed in sprouting capillaries and small blood vessels (Fig. 1b, left and right panels, arrows), whereas the endothelium of mature quiescent vessels showed no detectable levels of heparanase (Fig. 1b, left and middle panels, concave arrows) . A similar expression pattern was observed in human mammary and pancreatic carcinomas (not shown). This result suggests a significant role of endothelial heparanase in enabling ECs to traverse BM and ECM barriers during sprouting angiogenesis. Intense staining of heparanase was noted in the neoplastic colonic mucosa, as opposed to no detectable expression of the enzyme in normal colon epithelium and stroma (Fig. 1b) (15) .
Release of HS-bound bFGF and of bFGF-promoting fragments of HS by recombinant heparanase
The possible role of tumor-and stroma-derived heparanase in angiogenesis was addressed in the following experiments. A straightforward explanation for such a role is release of ECM-resident bFGF and other heparin-binding angiogenic factors (6, 10, 11) . To verify this mode of action, naturally produced subendothelial ECM was preincubated with 125 I-labeled bFGF, washed free of the unbound bFGF, and incubated (3 h, 37°C) with the 50-kDa active form of the recombinant heparanase enzyme. As demonstrated in Fig. 2a , degradation of HS in the ECM, reflected by release of sulfate-labeled HS degradation fragments (inset), resulted in release of as much as 70% of the ECM-bound 125 I-bFGF. Alternatively, the enzyme was added to native ECM that was not preincubated with 125 I-bFGF. Aliquots of the incubation medium were then tested for the presence of bFGF by using a quantitative ELISA for bFGF. Nearly 0.8 ng of endogenous bFGF was released from ECM coating the surface area of a 35-mm culture dish (Fig. 2b) . The released bFGF stimulated the proliferation of 3T3 fibroblasts and bovine aortic ECs by five-to eightfold (not shown). These results clearly indicate that heparanase releases active bFGF sequestered as a complex with HS in the ECM. Both tumor and endothelial heparanase may hence elicit an indirect angiogenic response by means of releasing HS-FGF complexes from storage in the ECM and tumor microenvironment.
The ability of heparanase-cleaved HS degradation fragments to promote the mitogenic activity of bFGF was investigated by using a cytokine-dependent lymphoid cell line (BaF 3 , clone 32) engineered to express FGF receptor 1 (FGFR1). These cells lack cell surface HS and respond to bFGF only in the presence of exogenously added species of heparin or HS (8, 24) . We first treated both a native ECM and a confluent vascular EC monolayer with the recombinant 50-kDa heparanase enzyme. Aliquots of the incubation media were then added to BaF 3 cells and tested for their ability to promote [ 3 H]thymidine incorporation in response to bFGF. As expected, BaF 3 cells exposed to either bFGF or heparanase alone exhibited almost no incorporation of [ 3 H]thymidine. A marked stimulation (~40 fold) of DNA synthesis was obtained in the presence of HS degradation fragments released by heparanase from EC surfaces (Fig. 2c) . Interestingly, HS fragments released by heparanase from the subendothelial ECM exerted a much smaller effect (Fig. 2c) . These results suggest that heparanase may potentiate the mitogenic activity of bFGF and possibly other heparin-binding angiogenic growth factors through release of HS degradation fragments that promote bFGF-receptor binding and activation.
Heparanase promoted tissue vascularity and tumor angiogenesis in vivo
The ability of recombinant 50-kDa heparanase to induce vascularization in vivo was demonstrated in a wound-healing mouse model. As demonstrated in Fig. 3 , local daily application of recombinant heparanase (~2 ng/mm 2 ) onto a full-thickness wound created in the dorsal skin resulted in a four-to sixfold increase in vascular density (Fig. 3B and D) and formation of a dense cellular granulation tissue (Fig. 3B) , compared with control wounds treated with buffer alone (Fig. 3A and C) . Heparanase-induced tissue remodeling and vascularization were also reflected by a significant acceleration of wound closure, measured on day 7 after the wound was created (not shown).
Finally, we applied the Matrigel plug assay (28) to investigate whether heparanase can elicit tumor angiogenesis in vivo. For this purpose, stable heparanase-transfected Eb lymphoma cells (15) were mixed at 4°C with Matrigel (reconstituted BM preparation extracted from EHS mouse sarcoma) and injected s.c. into BALB/c mice. Similarly treated mock-transfected Eb cells expressing no heparanase activity served as a control (15) . Upon injection, the liquid Matrigel rapidly forms a solid gel plug that serves as a supporting medium for the lymphoma cells. Its major components, similar to intact BM, are laminin, collagen type IV, and HSPGs. Matrigel also contains bFGF and other growth factors that are found in natural BM and ECM (30) . Hence, the Matrigel in this experimental system serves not merely as an inert vehicle for the enzymeproducing cells but also as an agent maintaining the natural interactions existing between tumor cells and the surrounding ECM, providing, among other effects, a source of ECM-sequestered bFGF. As shown in Fig. 4 , a pronounced angiogenic response was induced by Matrigelembedded Eb cells overexpressing heparanase compared with little or no neovascularization produced by mock-transfected Eb cells expressing no heparanase activity. The angiogenic response was reflected by a network of capillary blood vessels attracted toward the Matrigel plug containing heparanase-transfected Eb cells (Fig. 4a, left) vs. a very small or no vascular response elicited by control mock-transfected Eb cells (Fig. 4a, right) , and by a respective difference in the amount of blood and number of vessels seen in the isolated Matrigel plugs excised from each mouse (Fig. 4b , heparanase-producing, bottom, vs. control mock-transfected cells, top). This difference was highly significant, as also demonstrated by measurements of the hemoglobin content of Matrigel plugs removed from each mouse of the two groups (Fig. 4c) . These findings, together with our previous results on the increased metastatic potential of heparanase-transfected vs. mock-transfected Eb cells (15) , emphasize the significance of heparanase in the two critical events in tumor progression.
DISCUSSION
We previously reported the cloning of mammalian heparanase, an endo-β-D-glucuronidase degrading HS, and provided direct evidence for its role in tumor metastasis. We now demonstrate that heparanase is intimately involved in angiogenesis and elucidate its mode of action. Immunohistochemical staining of human tumors (colon, breast, pancreas) revealed strong expression of the heparanase protein in the endothelium of sprouting capillaries and small vessels but not of mature quiescent blood vessels, suggesting up-regulation of the heparanase gene and protein in the endothelium of angiogenic blood vessels. As previously described, intense preferential expression of heparanase was noted in carcinoma cells (15, 26) , which thus can be regarded as the main source of heparanase in the tumor microenvironment. Moreover, at a later stage of tumor progression, heparanase was also found in the tumor stroma (26) .
Apart from its direct involvement in ECM degradation and EC migration (vascular sprouting), heparanase was found to release active bFGF from the subendothelial ECM, as well as bFGFstimulating HS degradation fragments from the EC surface. It is interesting that HS fragments released from ECM induced little or no potentiation of the growth-promoting activity of bFGF, suggesting that HS in the ECM is primarily involved in sequestration, protection, and stabilization of heparin-binding growth factors, whereas cell surface HS plays a more active role in promoting the angiogenic activity of the growth factor by means of stimulating receptor binding, dimerization, and activation. This concept is supported by the recently reported preferential ability of cell surface HSPGs vs. ECM HSPGs to mediate the assembly of the bFGFreceptor signaling complex (9) . In preliminary studies, performed in collaboration with Drs. E. Buddecke and A. Schmidt, University of Munster, Germany, ECs were cultured in the presence of Na 2 35 SO 4 and were washed extensively, and both the cells and the ECM were treated with bacterial heparinase III. Sulfate-labeled degradation fragments were then subjected to size fractionation on Biogel P6. Different elution profiles were obtained, showing a three-to eightfold higher ratio of disaccharides to oligosaccharides in material released from cells vs. ECM. This and other structural differences may be responsible for the observed difference in biological activity. A more detailed analysis (i.e., mass spectroscopy and NMR spectroscopy; sequencing) of ECM-and cell surface-derived species of HS and their interaction with bFGF is ongoing.
Using the mouse Matrigel plug angiogenesis assay, we observed an increased angiogenic response to heparanase-transfected T-lymphoma cells embedded in Matrigel and implanted s.c. vs. a small or no response to the parental mock-transfected cells. This result is a clear demonstration of the involvement of heparanase in tumor angiogenesis. Increased tissue vascularity was also observed in a mouse wound-healing model in response to topical administration of recombinant heparanase. Thus, cooperative interactions between heparanases from tumor, inflammation, and endothelial sources appear to play a significant role in the angiogenic cascade. Similarly, MMP-9 is regarded as a specific component of the angiogenic switch by rendering VEGF more available to its receptors, and its inhibitors impair angiogenesis and tumor growth (31) .
The ability of heparanase to promote tumor angiogenesis and its involvement in tumor metastasis make it a promising target for cancer therapy. In other words, compounds that inhibit heparanase are expected to exert an anticancerous effect through inhibition of both tumor cell metastasis and angiogenesis. In fact, nonanticoagulant species of heparin and various sulfated polysaccharides that inhibit experimental metastasis also inhibit tumor cell heparanase (12, 14) . Among these compounds is phosphomannopentaose sulfate (PI-88), whose continuous administration inhibits the growth, vascularity, and lymph node metastasis of mammary adenocarcinoma tumors in rats (32) . This compound is being evaluated in a multicenter phase II clinical trial.
Heparanase is the first mammalian HS-degrading enzyme that has been cloned, expressed, and characterized. These results may pave the way for identification and cloning of other members of a putative family of mammalian glycosaminoglycan-degrading enzymes (e.g., chondroitinase, dermatanase, keratanase), toward a better understanding of the function and biological significance of both the enzymes and their polysaccharide substrates. Although cancer cells and inflammatory cells produce a large number of matrix-degrading enzymes (4, 33) , the unexpected identification of a single predominant functional heparanase suggests that if its activity can be inhibited, other heparanases may not be able to substitute for it. However, in view of the normal roles of the enzyme, heparanase-inhibiting compounds might, for example, interfere with physiological functions such as immune surveillance, tissue repair, anticoagulant activity, and HS turnover (20) . Given the potential tissue damage that could result from inadvertent cleavage of HS, strict regulation and balance are essential. Potential regulators are cytokines, local pH, and cellular localization (33, 34) . Regulatory elements in the promoter and other regions of the heparanase gene are being investigated, although very little is known at the present time. An attractive regulatory target is the apparently membrane-bound protease, which converts the heparanase from a latent form into an active form (15, 16) . The nature of this enzyme has not been identified. The significance of cell surface binding of the enzyme, its activation, and its cellular uptake and the associated effects on cell migration, metastasis, and angiogenesis are being investigated. It is hoped that identification of the sugar residues in HS adjacent to the heparanase cleavage site, as well as crystallization and analysis of the 3D structure of the enzyme, will lead to a rational design of highly specific heparanase inhibitors. Several groups are currently developing competitive heparin -mimicking compounds, neutralizing antiheparanase antibodies, antisense oligonucleotides, and heparanase-inhibiting small molecules. Also, because the enzyme itself promotes cell migration and angiogenesis, its administration and/or up-regulation in vivo may be applied, as demonstrated in the present study, to enhance wound healing and tissue vascularity. RT-PCR for expression of the heparanase mRNA, by using specific human hpa primers amplifying a 564-bp cDNA fragment (15) . Lane 3 shows DNA molecular weight markers. hep = heparanase; RT = reverse transcriptase. b) immunohistochemistry. Immunostaining of primary human colon adenocarcinoma specimens was performed as described in Materials and Methods. Positive staining is reddish brown. Preferential staining of the heparanase protein was seen in the endothelium of capillaries and small sprouting vessels (arrows, left and right panels); mature quiescent blood vessels showed little or no staining of EC (concave arrows, left and middle panels). The heparanase protein was highly expressed in the neoplastic colonic epithelium. Original magnification: 200 × (left and right panels) and 100 × (middle panel). 125 Ilabeled bFGF as described in Materials and Methods. The ECM was washed three times and incubated (3 h, 37°C) with increasing concentrations (0.01-0.4 µg/ml) of recombinant heparanase. Released radioactivity was expressed as a percentage of the total ECM-bound 125 I-labeled bFGF. About 10% of the ECM-bound 125 I-labeled bFGF was released in the absence of added heparanase. Each data point is the mean±SD of triplicate wells. Where error bars cannot be seen, the SD is smaller than the symbol. Inset) Release of sulfate-labeled HS degradation fragments. Sulfate-labeled ECM was incubated (3 h, 37°C, pH 6.0) with 0.2 µg/ml recombinant heparanase. Sulfate-labeled material released into the incubation medium was analyzed by gel filtration on Sepharose 6B. b) Release of endogenous ECM-resident bFGF by heparanase. Recombinant heparanase (0.5 µg/ml) was incubated (4 h, 37°C) with ECM-coated 35-mm dishes in 1 ml of heparanase reaction mixture. Aliquots of the incubation media were taken for bFGF quantitation by ELISA as described in Materials and Methods. Each data point is the mean±SD of triplicate determinations. c) Stimulation of bFGF-induced DNA synthesis in BaF3 lymphoid cells by cell surface-derived HS degradation fragments. Confluent bovine aortic EC ( cultured in 35-mm plates and their underlying ECM (•) were incubated (4 h, 37°C, pH 6.5) with 0.2 g/ml recombinant heparanase. Aliquots (5-200 l, corresponding to similar amounts of material released from cells and ECM; see inset) of the incubation media were then added to BaF3 cells seeded into 96-well plates in the presence of 5 ng/ml bFGF. 
